Wildfire smoke exposure leaves a measurable proteomic footprint in firefighters
Wildland firefighting is no longer just a respiratory hazard or a burn risk. In a growing body of occupational science, it is becoming a long-term cancer question, and a new biomarker study adds molecular detail to that concern. After a single fire response, firefighters showed altered proteins in blood and urine, with investigators identifying 330 protein groups in serum and 1085 in urine from paired samples collected before and after fire exposure.
The clinical importance lies in what those shifts may represent. Wildfire smoke carries benzene, soot, and other carcinogenic compounds, and repeated exposure can stress inflammatory, metabolic, and repair pathways long before any tumor is diagnosed. In this study, the proteomic changes were framed as signals of biological pathways associated with cancer and other diseases, rather than validated cancer markers. That distinction is essential. A changed protein profile is not a diagnosis, but it can point to the mechanistic traffic jam created by inhaled toxins, oxidative stress, and systemic injury.
One sentence captures the central concern: the body may be registering cancer-relevant injury well before routine screening ever would.
Urine exposed more of the response than serum did
The investigators focused on paired pre-exposure and post-exposure samples from 30 firefighters. Their interest in urine was practical and biologically plausible. Urine can reveal acute proteomic responses that may not appear, or may appear less clearly, in serum after fire-smoke exposure. Different body fluids do not simply duplicate one another. A protein may be filtered, modified, or concentrated in urine in ways that make it easier to detect a short-lived stress response.
Among the proteins altered after exposure, the fibrinogen gamma chain, or FGG, drew attention because it increased in urine and has previously been linked with multiple disease states, including cancer. The signal does not establish FGG as a biomarker for cancer in firefighters, and the study did not claim that level of validation. What it does suggest is that firefighting may activate disease-related pathways involving coagulation, inflammation, and tissue remodeling, all of which can intersect with carcinogenesis.
A biomarker is only as useful as its validation.
That reality matters here. Proteins can sit inside a pathway associated with malignancy without serving as a reliable standalone marker. To move from association to clinical utility, the field needs larger cohorts, longitudinal follow-up, and repeated sampling that shows whether these proteins remain elevated, normalize, or predict later disease.
Occupational cancer risk is moving from epidemiology to biology
The broader occupational context is already established. In 2022, an international working group associated with the International Agency for Research on Cancer classified firefighting as carcinogenic to humans. The epidemiology has been accumulating for years, but molecular studies are now trying to explain how the exposure translates into biological injury. That shift matters for occupational medicine because it could eventually support more precise surveillance than general population screening alone.
Sarah Jahnke, who has studied firefighters’ health markers for nearly two decades, points to the chemical load involved in wildfire response. Even with masks and protective equipment, firefighters are exposed to carcinogens such as benzene and soot, along with so-called forever chemicals. Those exposures are not theoretical. They are inhaled, absorbed, and carried through repeated deployments, especially in wildland settings where the gear and respiratory protection differ from structural firefighting.
The pathophysiology is straightforward enough to be concerning. Inhaled smoke can trigger oxidative stress and inflammatory cascades, and repeated injury can alter proteins involved in immune signaling, clotting, and cellular repair. Over time, those pathways may contribute to carcinogenic change. The study’s proteomic approach does not diagnose that process directly, but it does offer a biological snapshot of how the body responds immediately after exposure.
What this means for screening and surveillance
Jackie Goodrich, an environmental epidemiologist, places the findings in a practical frame: early detection tools could matter for firefighters because their exposure burden is unusually high, and wildland crews often do not have the same level of respiratory protection as other emergency responders. Blood and urine collected soon after a fire may help show how the body is responding when exposure is freshest, which is the window when transient versus persistent biological changes can first be distinguished.
Still, the key clinical question is persistence. Are these proteins simply the residue of an acute insult, or do they remain elevated after the smoke clears? Without follow-up over years, no one can say whether the observed proteomic shifts fade harmlessly or mark a longer trajectory toward disease. That uncertainty is not academic. It determines whether the field is looking at a short-lived stress reaction or an early warning system for occupational cancer.
For now, the study supports a cautious but important proposition: firefighters may carry molecular signatures of exposure in their body fluids, and urine in particular may be a useful matrix for detecting them. The work also reinforces a public health challenge that is becoming harder to ignore as wildfire seasons lengthen and intensify. More responders are being sent into smoke-filled environments, and the occupational risk does not end when the fire is out.
The unanswered issue is whether these protein changes can be converted into durable surveillance tools that reduce cancer risk rather than merely documenting exposure after the fact.